Vaxil Bio Ltd.
VXLLF
$0.10
$0.000.00%
OTC PK
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -13.11% | -45.29% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.11% | -48.26% | |||
| Operating Income | 13.11% | 48.26% | |||
| Income Before Tax | -155.77% | 153.28% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -155.77% | 153.28% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -147.70% | 162.30% | |||
| EBIT | 13.11% | 48.26% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -147.75% | 162.36% | |||
| Normalized Basic EPS | -155.93% | 153.15% | |||
| EPS Diluted | -147.75% | 162.36% | |||
| Normalized Diluted EPS | -155.93% | 153.15% | |||
| Average Basic Shares Outstanding | 0.00% | 0.00% | |||
| Average Diluted Shares Outstanding | 0.00% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||